News
Future Fertility appoints TMRW Life Sciences executive Louis Villalba to its board of directors
Villalba brings more than 30 years of industry experience in developing and commercialising innovative products and therapies

Toronto-based Future Fertility has added tenured industry executive Louis Villalba to their board of directors.
Future Fertility develops AI-based decision support tools to help optimise the fertility journey, with a focus on the oocyte – the human egg.
The company’s non-invasive oocyte assessment software is the first to deliver personalised AI-powered egg quality insights, paving the way for a new standard of care by empowering patients and providers with individualised predictions for blastocyst formation and live birth.
“We have big ambitions globally as we shift into commercial growth mode in 2023,” says Christy Prada, CEO of Future Fertility.
“Lou brings the perfect mix of industry and commercial experience to round out our board team. We are lucky to have the opportunity to learn from him as we further grow our work with fertility clinics and patients globally.”
Louis S. Villalba brings more than 30 years of industry experience in developing and commercialising innovative products and therapies.
Mr Villalba is currently serving as chief business officer at TMRW Life Sciences. Previously he served as chief executive officer of Genea Biomedx, EVP of Corporate Development at OvaScience, EVP of sales at Auxogyn / Progyny and EVP of Europe for Conceptus from 2004 to 2013 where he was part of the team that completed the $1.1B sale of the company to Bayer AG.
“Future Fertility has developed a very interesting and compelling technology, hitting an important niche in the market. They are the first and only commercially available AI product in the oocyte assessment space and have a clear first-mover advantage,” says Villalba.
“I look forward to working with Christy and the senior management team to focus on developing commercial strategies that make Future Fertility’s AI software a standard of care in reproductive health around the world.”
Villalba’s industry expertise complements Future Fertility’s current board of directors as the company rapidly grows its presence globally, combining Whitecap Ventures’ expertise in scaling technology start-ups, M Ventures’ experience in MedTech commercialisation and co-founder Rene Bharti’s global business experience.
For more info, visit futurefertility.com.

Diagnosis
AI may help accelerate breast cancer diagnosis for high-risk women – study
Fertility
Infertility may be risk factor for early menopause, study suggests
News
Endometriosis documentary profiles stars including Marilyn Monroe and Amy Schumer

A non-profit has launched an endometriosis documentary featuring Amy Schumer and Marilyn Monroe as it pushes for changes in how the condition is treated and understood.
The Endometriosis Collective has launched to change how endometriosis is researched, treated and understood, starting with a documentary featuring stories from people including Amy Schumer and Marilyn Monroe.
The feature-length documentary, “End of the Cycle”, will premiere in New York on Tuesday, and The Endometriosis Collective is making the film free to stream online.
Schumer, a comedian, writer and actor, has previously spoken of how endometriosis left her “on the floor in pain, vomiting from the pain, the pain that nobody can see.”
Schumer is one of several celebrities featured in the documentary. Other contributors include dancer Julianne Hough, Olympic medallist Brittany Brown and actors Janel Parrish and Folake Olowofoyeku.
The Endometriosis Collective timed the documentary premiere to coincide with the 100th anniversary of Marilyn Monroe’s birth.
Monroe, who died in 1962, starred in films such as “Some Like It Hot” and “Gentlemen Prefer Blondes.”
According to a biography published in 1985, Monroe’s endometriosis was so severe that it destroyed her marriages, her wish for children, her career and ultimately her life.
The Endometriosis Collective said the documentary shares newly uncovered information about Monroe’s experience with endometriosis.
The non-profit said the information connects Monroe’s story to the experiences of women across generations, highlighting how far awareness, research and care still have to go.
A representative of the Marilyn Monroe Estate said: “By sharing this part of her story through ‘End of the Cycle,’ we hope to honour her legacy in a way that brings visibility to endometriosis, encourages more open dialogue and helps inspire the research needed to create change.”
As part of the premiere, The Endometriosis Collective is holding a panel discussion.
Schumer, Brown and Olowofoyeku, the documentary’s co-directors Sammy Jaye and Soraya Simi, and medical experts are due to be part of the premiere.
AbbVie’s Orilissa and Sumitomo Pharma’s Myfembree are among the approved drugs for endometriosis pain.
Hough, one of the participants in the documentary, starred in an Orilissa campaign in 2017.
Menopause1 week agoPerimenopause misinformation ‘putting women at risk’
News4 weeks agoNIH Grant terminations disproportionately impact minority scientists, research finds
Adolescent health4 weeks agoWUKA brings Period-Positive Pool Party to London Aquatics Centre to keep girls swimming through puberty
Insight3 weeks agoPCOS renamed after decade-long campaign to end ‘cyst’ misconception
Events4 weeks agoWHIS 2026 unveils agenda and first speakers for the leading women’s health summit
Mental health4 weeks agoCBT shows promise for menopause insomnia and hot flashes
Diagnosis2 weeks agoNHS urged to update website following renaming of PCOS
News6 days agoThree menopause innovators shortlisted for Femtech World Award














